U.S., July 19 -- ClinicalTrials.gov registry received information related to the study (NCT07072728) titled 'Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder' on Feb. 12.
Brief Summary: This study is assessing the efficacy and safety of PEX010 in psilocybin-assisted psychotherapy for the treatment of adjustment disorder due to cancer diagnosis.
Who is it for? This study is for people who are aged between 18 and 80 years old and suffer from anxiety after adjusting to an acutely stressful event of their cancer diagnosis. This is called adjustment disorder.
Study details Participants in this study will be randomly allocated by chance (similar to flipping a coin) to one of three groups: a 25mg PEX010 dose group, ...